Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy

Abstract

The objective of this study is to evaluate the effects of solifenacin on double-J stent-related symptoms following uncomplicated ureterosocpic lithotripsy (URSL). A total of 70 patients who underwent double-J ureteral stent insertion following URSL were consecutively recruited and received solifenacin postoperatively. Another 70 age- and sex-matched subjects without solifenacin therapy were enrolled as a control group. The clinical data including stone and stent characteristics were collected. All subjects completed the brief-form Ureteral Symptom Score Questionnaire (Chinese-version) to assess the lower urinary tract symptoms, stent-related body pain and hematuria 2 weeks after operation. The severity of stent-related symptoms was compared between two groups. The mean age was 53.8 in solifenacin group and 53.4 years in the control group (p = 0.87). The stone characteristics, stent size, position and curl completeness were similar in both groups. Compared to the control group, solifenacin group had significantly lower total symptom score, urgency and urge incontinence scores. As for stent-related body pain, solifenacin group had significantly less flank, abdominal, urethral pain and hematuria scores (all p < 0.05). The solifenacin versus control group showed significant benefits in lower urinary tract symptoms, stent-related pain and hematuria in both genders (all p < 0.05). Four subjects encountered minor adverse events (5.7 %) and one had urinary retention (1.4 %) in solifenacin group. For patients undergoing URSL and double-J stent indwelling, postoperative solifenacin use was effective and well-tolerated for the treatment of lower urinary tract symptoms, stent-related body pain and hematuria irrespective of genders.

Prevention and treatment of symptoms associated with indwelling ureteral stents: A systematic review

“…solifenacin, tolterodine) alone or in combination with a 1 -blockers. [17][18][19] These trials were summarized in a meta-analysis by Zhou et al in 2015. 20 The authors concluded that antimuscarinics alone improve IPSS total score as well as QoL and VAPS, and that combination therapy with a 1 -blockers seems to be superior compared with the respective monotherapies.…”

Doxazosin oral intake therapy to relieve stent - related urinary symptoms and pain: a prospective, randomized, controlled study

“…The secondary endpoints included QoL, analgesics use and treatment emergent adverse event (TEAE). To assess urinary symptoms and pain associated with ureteral stent, patients were asked to complete the brief-form Chinese version USSQ 2 weeks and 4 weeks after stent placement and 4 weeks after stent withdrawal (11). The outcomes obtained at 4 weeks after stent withdrawal were proposed to be the baseline data without the impact of ureteral stone and related hydronephrosis (6).…”

“…The brief-form Chinese version USSQ, a simplified condition-specific questionnaire for evaluation of stent-related urinary symptoms and pain in the past 2 weeks, was adopted from the validated International Prostate Symptom Scale (IPSS) (11). The procedure of back translation was performed to verify the utility for covering the urinary symptoms section and pain section of the original USSQ initiated by Joshi et al (11, 12).…”

“…The procedure of back translation was performed to verify the utility for covering the urinary symptoms section and pain section of the original USSQ initiated by Joshi et al (11, 12). Accordingly, QoL of IPSS was also assessed in our study (13).…”

“…A sample size of 218 patients was calculated based on a power of 80% and a significant level of 0.05 to detect 30% difference in flank pain scores and 26% difference in frequency scores in the first 2 weeks with the stent in situ (11). Descriptive statistics included mean±SD for continuous variables, number and percentage for categorical variables.…”